Browsing by Author "Muga, Silvia de"

Sort by: Order: Results:

  • A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression. American journal of pathology
    Agell, Laia; Hernández, Silvia; Nonell Mazelón, Lara; Lorenzo Perez, Marta; Puigdecanet Riubugent, Eulàlia; Muga, Silvia de; Juanpere, Nuria; Bermudo, Raquel; Fernández, Pedro Luís; Lorente Garin, José Antonio; Serrano Figueras, Sergi; Lloreta Trull, Josep, 1958- (Elsevier, 2012)
    The main challenge for clinical management of prostate cancer is to distinguish tumors that will progress faster and will show a higher tendency to recur from the more indolent ones. We have compared expression profiles ...
  • ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression
    Hernández Llodrà, Silvia; Juanpere, Nuria; Muga, Silvia de; Lorenzo Perez, Marta; Gil Ortega, Joan; Font Tello, Alba 1990-; Agell, Laia; Albero-González, Raquel; Segalés, Laura; Merino, José; Serrano, Laia; Fumadó Ciutat, Lluis; Cecchini Rosell, Lluís; Lloreta Trull, Josep, 1958- (Impact Journals, 2017)
    TMPRSS2 and SLC45A3 rearrangements may coexist in the same tumor. ERG rearrangements and PTEN loss are concomitant events in prostate cancer (PrCa), and can cooperate in progression. We have reported that mRNA expression ...
  • FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression
    Lloreta Trull, Josep, 1958-; Font-Tello, Alba; Juanpere, Nuria; Frances, Albert; Lorenzo Perez, Marta; Nonell Mazelón, Lara; Muga, Silvia de; Vázquez‐de las Heras, Ivonne; Cecchini Rosell, Lluís; Hernández, Silvia (Elsevier, 2017)
    Nuclear FOXOs mediate cell cycle arrest and promote apoptosis. FOXOs and p53 could have similar effects as tumor suppressor genes. In spite of extensive literature, little is known about the role of FOXO1 and its relationship ...
  • HER2 as a target in invasive urothelial carcinoma
    Bellmunt Molins, Joaquim, 1959-; Werner, Lillian; Bamias, Aristotle; Fay, André P.; Park, Rachel S.; Riester, Markus; Selvarajah, Shamini; Barletta, Justine A.; Berman, David M.; Muga, Silvia de; Salido, Marta; Gallardo, Enrique; Rojo, Federico; Guancial, Elizabeth A.; Bambury, Richard; Mullane, Stephanie A.; Choueiri, Toni K.; Loda, Massimo; Stack, Edward; Rosenberg, Jonathan E. (Wiley, 2015)
    We evaluated primary tumors from two cohorts, Spain (N = 111) and Greece (N = 102), for patients who were treated with platinum-based chemotherapy. Patients were tested for HER2 status (IHC score of 3+ or FISH ratio of ...
  • Identification of ALK gene alterations in urothelial carcinoma
    Bellmunt Molins, Joaquim, 1959-; Selvarajah, Shamini; Rodig, Scott; Salido Galeote, Marta; Muga, Silvia de; Costa, Irmgard; Bellosillo Paricio, Beatriz; Werner, Lillian; Mullane, Stephanie A.; Fay, André P.; O’Brien, Robert; Barretina, Jordi; Minoche, André E.; Signoretti, Sabina; Montagut Viladot, Clara; Himmelbauer, Heinz; Berman, David M.; Kantoff, Philip; Choueiri, Toni K.; Rosenberg, Jonathan E. (Public Library of Science (PLoS), 2014)
    Anaplastic lymphoma kinase (ALK) genomic alterations have emerged as a potent predictor of benefit from treatment with ALK inhibitors in several cancers. Currently, there is no information about ALK gene alterations in ...